

**N8 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/equine/Pennsylvania/1/2007 (H3N8), Recombinant from Baculovirus**

**Catalog No. NR-13523**

This reagent is the tangible property of the U.S. Government.

**Product Description:**

A recombinant form of the N8 neuraminidase (NA) protein from influenza virus A/equine/Pennsylvania/1/2007 (H3N8) containing an N-terminal histidine tag was produced in High-Five™ insect cells using a baculovirus expression vector system and was purified by metal affinity chromatography.

**Lot: 70077297**

**Manufacturing Date: 05FEB2026**

TEST	SPECIFICATIONS	RESULTS
<b>Appearance</b>	Report results	Clear and colorless
<b>SDS-PAGE Analysis</b>	Protein band of interest represents > 90% of total staining intensity	Dominant band of ~ 51 kDa accounts for 90.8% of total staining intensity (Figure 1)
<b>Identification by Western Blot</b> Monoclonal anti-histidine tag <sup>1</sup> Polyclonal anti-N8 NA <sup>2</sup>	Reactive Reactive	Reactive (Figure 2A) Reactive (Figure 2B)
<b>Concentration by Bradford Assay<sup>3</sup></b>	Report results	0.125 mg/mL
<b>Final Product</b> Quantity per vial Volume per vial	Report results Report results	56.3 µg 450 µL
<b>Functional Activity</b> Neuraminidase activity in a fluorescent enzymatic assay <sup>4</sup>	Report results	1.18 × 10 <sup>10</sup> relative fluorescence units/hour/mg protein
<b>Endotoxin Content (Limulus Amoebocyte Lysate Assay)</b>	Report results	< 46.64 EU/mg
<b>Filtration</b>	0.2 µm sterile-filtered	0.2 µm sterile-filtered


<sup>1</sup>Using a 1:1000 dilution of mouse monoclonal anti-histidine (R&D Systems MAB050) as primary antibody and a 1:1000 dilution of HRP-conjugated anti-mouse IgG (R&D Systems HAF007) as secondary antibody.

<sup>2</sup>Using a 1:1000 dilution of goat polyclonal anti-NA (BEI Resources NR-3145) as primary antibody and a 1:1000 dilution of HRP-conjugated anti-goat IgG (R&D Systems HAF109) as secondary antibody.

<sup>3</sup>Using bovine serum albumin (BSA) as a standard.

<sup>4</sup>Using serial dilutions of NR-13523 and 2'-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (4-MUNANA), as described in Wetherall, N. T., et al. "Evaluation of Neuraminidase Enzyme Assays Using Different Substrates to Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network." *J. Clin. Microbiol.* 41 (2003): 742-750. PubMed: 12574276.


**Figure 1: SDS-PAGE Analysis**



Lane 1: Precision Plus Protein™ Standard  
 Lane 2: NR-13523 (1.0 µg)  
 Lane 3: BSA (1.0 µg)


**Figure 2: Western Blot Analysis**

**A: Monoclonal Anti-Histidine Tag**



Lane 1: MagicMark™ XP Protein Standard  
 Lane 2: BSA (0.5 µg)  
 Lane 3: NR-13523 (0.5 µg)

**B: Polyclonal Anti-N8 NA**



Lane 1: MagicMark™ XP Protein Standard  
 Lane 2: BSA (0.25 µg)  
 Lane 3: NR-13523 (0.25 µg)

/Sonia Bjorum Brower/  
Sonia Bjorum Brower

Technical Manager or designee, ATCC Federal Solutions

09 MAR 2026

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.  
 You are authorized to use this product for research use only. It is not intended for human use.

